Overview
Updated 14 Jul 2026
Michael J. Overman, MD, is Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology. The public record shows 1,076 publications with 32,085 citations (h-index 79), centered on Colorectal Cancer Treatments and Studies, Genetic factors in colorectal cancer, Cancer Genomics and Diagnostics. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 23 companies, 3 NIH-funded awards (2016–2024).
- Most recent indexed publication: 2026 · The oncologist
- Top research focus: Colorectal Cancer Treatments and Studies
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 299.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 2Active, not recruitingNCT05961709 - Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 1/PHASE2TerminatedNCT04800627 - Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 2Active, not recruitingNCT04729322
Industry payments
Updated 14 Jul 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202515 payments$14,200openpaymentsdata.cms.gov ↗
- Exelixis Inc.Program year202511 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20251 payment
NIH funding
Updated 14 Jul 2026
3 NIH research awards on record, funded 2016–2024 per NIH RePORTER. The latest:
- A technological approach for performance status assessment in advanced cancer patients
University of Tx Md Anderson Can Ctr
FY2024$546,557R01CA243554 - A technological approach for performance status assessment in advanced cancer patients
University of Tx Md Anderson Can Ctr
FY2023$559,111R01CA243554 - Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
University of Tx Md Anderson Can Ctr
FY2023$332,973P50CA221707
Congress activity
Updated 14 Jul 2026
333 congress contributions (2004–2025) across AACR, ASCO, ASH, ASTRO, ESMO, SABCS per OpenAlex. The most recent:
- Abstract B076: Clinical and Molecular Characteristics of <i>KRASQ61</i> Mutated Pancreatic Cancer and Other Gastrointestinal Malignancies
AACR (meeting unresolved)
AACR2025Co-author - A phase I trial of binimetinib plus hydroxychloroquine inpatients with previously treated metastatic pancreatic cancer.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Prognosis and treatment response stratification according to loss of proofreading (LOP) POLE variants.
Journal for immunotherapy of cancer
2025
Most-cited worksby citation count (OpenAlex)
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
1515 Holcombe Blvd., Unit 426, Houston, TX 77030
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- Past-Chair
Executive Committee of the Medical Staff (ECMS), MD Anderson
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - NCCN Guidelines Panel Member
Colon/Rectal/Anal/Small Bowel Cancers Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Media & interviewspress, podcasts and appearances
- Recurring video/interview contributor
OncLive (multiple pieces on colorectal cancer, immunotherapy, molecular testing, nonoperative GI cancer management)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Author/contributor
Targeted Oncology (GI cancer immunotherapy and biomarkers coverage)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- X / Twitter
x.com/michael_overman
Mentions by otherswhere others cite or feature them
- X / Twitter
x.com/MDAndersonNews/status/1916697696284578224
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
Universitair Ziekenhuis Leuven
- 1,845
- publications
- 177
- h-index
- 14
- trials
Josep Tabernero, MD, PhD
Vall d'Hebron Institut de Recerca
- 2,704
- publications
- 148
- h-index
- 19
- trials
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Charles Fuchs, MD, MPH
Yale Cancer Center
- 1,721
- publications
- 172
- h-index
- 7
- trials